C. Biaggi

发表

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

C. Mamot, G. Martinelli, S. Dirnhofer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

M. Ghielmini, P. Zinzani, G. Martinelli, 2012, Haematologica.

Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial.

J. Bedke, R. Cathomas, A. Dieing, 2022, The Lancet. Oncology.

Long‐term outcome of dasatinib first‐line treatment in gastrointestinal stromal tumor: A multicenter, 2‐stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07)

John O. Prior, M. Toulmonde, P. Rutkowski, 2018, Cancer.

Sequence and Specificity Analysis of Recombinant Human Fab Anti–Rh D Isolated by Phage Display

S. Miescher, M. Vogel, B. Stadler, 1998, Vox Sanguinis.

A Multi-Center Phase II Study (SAKK 36/06) of Single Agent Everolimus (RAD001) In Patients with Relapsed or Refractory Mantle Cell Lymphoma.

P. Zinzani, G. Martinelli, S. Cogliatti, 2010 .

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small‐cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial

R. Stahel, S. Peters, D. Betticher, 2017, Clinical lung cancer.

LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

J. Bedke, R. Cathomas, A. Dieing, 2021, Annals of Oncology.

Dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter phase II trial of the SAKK (SAKK 56/07).

John O. Prior, A. Cesne, P. Rutkowski, 2012 .

Human anti‐IgE antibodies by repertoire cloning

S. Miescher, M. Vogel, B. Stadler, 1994, European journal of immunology.

The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14

J. Passweg, R. Skoda, A. Tzankov, 2018, Haematologica.

1418PDLONG-TERM OUTCOME OF DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER TWO STAGE PHASE II TRIAL SAKK 56/07.

John O. Prior, B. Bui, P. Rutkowski, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14

J. Passweg, R. Skoda, A. Tzankov, 2016 .